CVRx, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 42/100
What the filing says
CVRx reported Q2 2026 revenue of $15.7M (16% YoY growth; U.S. $14.8M +21%), with 466 U.S. units sold and 258 active implanting centers (vs. 240 YoY). Humana issued Medicare Advantage coverage for Barostim effective May 1, 2026, covering ~5.2M members across 46 states. However, the company lowered full-year 2026 guidance to $58–60M revenue (from prior implied higher outlook) due to fewer sales territories than anticipated, lower sales force productivity, and payer challenges. Cash balance declined to $64.6M (from $75.7M at year-end 2025); long-term debt increased to $58.6M (from $49.5M). Net loss was $14.0M ($0.53/share, 26.5M shares outstanding) vs. $14.7M YoY.
Why this rating
Revenue growth (16%) is positive, but guidance reduction and operational headwinds (sales force productivity, payer challenges) outweigh. Cash burn ($8.9M Q2 operating/investing) and rising debt are material at $112M market cap. Humana deal is modest offset.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.